Advertisement

Annals of Surgical Oncology

, Volume 18, Issue 2, pp 566–571 | Cite as

Prognostic Significance of the Alterations of the G1-S Checkpoint in Localized Leiomyosarcoma of the Peripheral Soft Tissue

  • John Panelos
  • Giovanni Beltrami
  • Guido Scoccianti
  • Rodolfo Capanna
  • Milena Paglierani
  • Monica Pepi
  • Daniela Massi
  • Alessandro Franchi
Translational Research and Biomarkers

Abstract

Background

The aim of this study was to investigate the expression of cell cycle regulators p53, p16, cyclin-D1, and retinoblastoma (Rb) gene protein in leiomyosarcoma of the peripheral soft in order to identify expression profiles potentially useful for clinical prognostic purposes.

Materials and Methods

A tissue microarray representing 70 localized leiomyosarcomas of the limbs and limb girdles was created with 3 representative cores from each tumor. Immunohistochemical staining was performed for p53, p16, cyclin-D1, and Rb using standard techniques. Staining was scored as either absent-low (<20% of neoplastic cells) or moderate-diffuse (≥20%). Outcome analysis was performed for local recurrence-free survival (LFS), metastatic disease-free survival (MDFS), and disease-specific survival (DSS).

Results

Kaplan–Meier analysis of survival revealed that no single alteration of the factors examined was associated with outcome, but tumors showing concomitant alteration of p16 and p53 were characterized by reduced MDFS and DSS (P = 0.01 and P < 0.001, respectively). In addition, patients who received adjuvant therapy consisting of radiotherapy alone or radiotherapy and chemotherapy had a better DSS than those receiving surgery alone or surgery and chemotherapy (P = 0.05). In multivariate analysis, altered p16/p53 remained the only parameter predictive of MDFS and DSS (P = 0.048, hazard ratio [HR] = 2.488, 95% confidence interval [95% CI] 1.006–5.116; P = 0.043, HR = 2.498, 95% CI 1.029–5.909, respectively).

Conclusions

Accumulation of cell cycle alterations represents a prognostic indicator in localized soft tissue leiomyosarcoma, and in particular altered p16/p53 expression is associated with an unfavorable prognosis. This may help the clinical management of patients with leiomyosarcomas.

Keywords

Leiomyosarcoma Ventana Medical System Deep Soft Tissue Nuclear Immunoreactivity Peripheral Soft Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Svarvar C, Bohling T, Berlin O, Gustafson P, Follerås G, Bjerkehagen B, et al. Clinical course of non visceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer. 2007;109:282–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Massi D, Beltrami G, Mela MM, Pertici M, Capanna R, Franchi A, et al. Prognostic factors in soft tissue leiomyosarcoma of the extremities: a retrospective analysis of 42 cases. Eur J Surg Oncol. 2004; 30:565–72.CrossRefPubMedGoogle Scholar
  3. 3.
    Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689–95.PubMedGoogle Scholar
  4. 4.
    Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer. 1994;69:1052–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Dei Tos AP, Maestro R, Doglioni C, Piccinin S, Libera DD, Boiocchi M. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol. 1996;148:1037–45.PubMedGoogle Scholar
  6. 6.
    Konomoto T, Fukuda T, Hayashi K, Kumazawa J, Tsuneyoshi M. Leiomyosarcoma in soft tissue: examination of p53 status and cell proliferating factors in different locations. Hum Pathol. 1998;29:74–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T, et al. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol. 2003;201:487–95.CrossRefPubMedGoogle Scholar
  8. 8.
    Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15:350–62.PubMedGoogle Scholar
  9. 9.
    Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120.Google Scholar
  10. 10.
    Yang J, Du X, Chen K, Ylipää A, Lazar AJ, Trent J, et al. Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett. 2009;275:1–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Otaño-Joos M, Mechtersheimer G, Ohl S, Wilgenbus KK, Scheurlen W, Lehnert T, et al. Detection of chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics. Cytogenet Cell Genet. 2000;90:86–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Mandahl N, Fletcher CD, Dal Cin P, De Wever I, Mertens F, Mitelman F, et al. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP Study Group. Cancer Genet Cytogenet. 2000;116:66–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Bates S, Parry D, Bonetta L, Bates S, Parry. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene. 1994;9:1633–40.PubMedGoogle Scholar
  14. 14.
    Müller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M, et al. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA. 1994;91:2945–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst. 1994;86:549–54.CrossRefPubMedGoogle Scholar
  16. 16.
    Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res. 1998;4:1985–94.PubMedGoogle Scholar
  17. 17.
    Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 2000;60:3655–61.PubMedGoogle Scholar
  18. 18.
    Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA. p16INK4a and p53 deficiency cooperate in tumorigenesis. Cancer Res. 2002;62:2761–5.PubMedGoogle Scholar
  19. 19.
    Voorhoeve PM, Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell. 2003;4:311–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Peterson EJ, Bogler O, Taylor SM. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res. 2003;63:6579–82.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • John Panelos
    • 1
  • Giovanni Beltrami
    • 2
  • Guido Scoccianti
    • 2
  • Rodolfo Capanna
    • 2
  • Milena Paglierani
    • 1
  • Monica Pepi
    • 1
  • Daniela Massi
    • 1
  • Alessandro Franchi
    • 1
  1. 1.Department of Human Pathology and OncologyUniversity of Florence Medical SchoolFlorenceItaly
  2. 2.Department of Orthopedic OncologyAzienda Ospedaliera Universitaria CareggiFlorenceItaly

Personalised recommendations